S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone
therapy. It is not yet known whether duloxetine hydrochloride is more effective than a
placebo in treating patients with muscle, bone, and joint pain caused by hormone therapy.
PURPOSE: This randomized phase III trial studies how well duloxetine hydrochloride works
compared to a placebo in treating muscle, bone, and joint pain in patients with early-stage
breast cancer receiving hormone therapy.